Surveying the Status of a Large Number of Mutations by A Single PEPD Assay

通过单一 PEPD 检测调查大量突变的状态

• 批准号: 7110741
• 负责人: BAOCHUAN GUO
• 金额: $ 70.48万
• 依托单位: GLC BIOTECHNOLOGY, INC.
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-26 至 2008-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7110741
• 关键词: DNA; gene mutation; neoplasm /cancer; success

DESCRIPTION (provided by applicant): This application is to develop the PEPD technology to survey the mutation status of hundreds of DMA markers in a vast excess of wild-type DNA for cancer screening. Specifically, we will develop a fecal DMA testing assay for colorectal cancer (CRC) screening. Fecal DNA testing is emerging as a novel method for CRC screening. However, fecal DNA testing is a technical challenge, as no single marker can indicate all CRCs and thus a large panel of markers must be utilized to increase sensitivity. As a result, existing fecal DNA methods are not suitable for screening because of either poor sensitivity or high-cost. In Phase I, we demonstrated that a novel technology called PEPD could survey a number of mutations in a 10,000 folds more excess of normal DNA by a single assay, making it possible to detect mutations in a sensitive and cost effective manner. To the best of our knowledge, this provides the first demonstration of surveying the status of a large number of DNA markers with such high sensitivity by a single assay. The PEPD method is simple, but very powerful and thus it can be a universal mutation detection technology platform. Hence, success of this project will have a profound impact on mutation analysis and thus cancer screening. The PEPD-based assay developed in Phase II can detect 80-85% of CRCs in a cost-effective manner. Success of this work is of great significance in CRC screening, as it can transform fecal DNA testing. Eventually, it allows physicians to detect the majority of CRC simply by taking a piece of stool for DNA analysis to save thousands of life each year from CRC. In addition, this assay can be used to monitor CRC patients and risk assessment after treatment.

描述（由申请人提供）：本申请旨在开发PEPD技术，以调查大量过量野生型DNA中数百个DMA标记物的突变状态，用于癌症筛查。具体来说，我们将开发一种粪便DMA检测方法用于结直肠癌（CRC）筛查。粪便DNA检测正在成为CRC筛查的一种新方法。然而，粪便DNA检测是一个技术挑战，因为没有一个单一的标志物可以指示所有的CRC，因此必须利用一个大的标志物面板来提高灵敏度。因此，现有的粪便DNA方法不适合筛查，因为灵敏度差或成本高。在第一阶段，我们证明了一种名为PEPD的新技术可以通过一次检测在超过正常DNA 10，000倍的范围内调查许多突变，从而可以以灵敏和经济有效的方式检测突变。据我们所知，这提供了第一次证明调查的大量DNA标记的状态，具有如此高的灵敏度，由一个单一的测定。PEPD方法简单，但非常强大，因此它可以成为通用的突变检测技术平台。因此，该项目的成功将对突变分析和癌症筛查产生深远的影响。在第二阶段开发的基于PEPD的检测方法可以以具有成本效益的方式检测80-85%的CRC。这项工作的成功在CRC筛查中具有重要意义，因为它可以改变粪便DNA检测。最终，它允许医生通过简单地采取一块粪便进行DNA分析来检测大多数CRC，每年从CRC中挽救数千人的生命。此外，该检测可用于监测CRC患者和治疗后的风险评估。